June 12, 2026
1 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
FDA approves belzutifan with pembrolizumab as adjuvant for renal cell carcinoma
The FDA approved belzutifan with pembrolizumab as an adjuvant treatment for adults with clear cell renal cell carcinoma and a high risk for recurrence after nephrectomy, according to a press release.The approval allows belzutifan (Welireg, Merck) to be used in combination with pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck).
427 words~2 min read
